Home » Joint Genome Institute, National Center for Biotechnology Information, Wellcome Trust Sanger Institute

Joint Genome Institute, National Center for Biotechnology Information, Wellcome Trust Sanger Institute

Mar 20, 2007
Premium

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

UK Bioethics Group Gives Cautious OK for Genetically Modifying Human Embryos

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

CRISPR-Induced Damage?

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

'Fax' It Over

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

This Week in PNAS

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.

Sep
17
Featured Webinar

Trends in Clinical NGS QC Management: Expert Insights to Ensure Quality Results for Your Lab

Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

What's Popular?

In Clinical Sequencing

  1. Following Clinical Pilot Study, CeGaT Launches Genetic Disease Prevention Panel

    Premium

  2. Illumina, OrigiMed Collaborate to Develop Cancer Assays

  3. Public Health England Team Describes Metagenomic Sequencing Strategy to ID Viral Pathogens

    Premium

  4. Natera Prices Public Offering of 4.5M Shares

  5. Natera Aims to Raise $75M in Public Stock Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.